Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Clostridium difficile associated diarrhoea is an important cause of morbidity in patients
treated with antibiotics, especially in hospital. Clinical relapse occurs after up to 30% of
initially successful treatments for colitis. Preliminary reports suggest that Rifaximin, a
poorly absorbed antibiotic used to treat travellers diarrhoea can prevent relapse. We plan to
carry out a randomised placebo controlled trial to test the hypothesis that Rifaximin given
in a reducing dose over 4 weeks after successful treatment will reduce the relapse rate.
Phase:
Phase 4
Details
Lead Sponsor:
University of Nottingham
Collaborator:
National Institute for Health Research, United Kingdom